University of Washington
Seattle, Washington, 98195, United States
NCT Number: NCT01167829
The purpose of this study is to test how the body absorbs a new form of oral testosterone (T). On Day 1 and Day 9 there are overnight stays in the General Clinical Research Center at the University of Washington to monitor blood testosterone levels over a 24-hour period.
Looking for future studies?
Notify Me18 year–55 year
Male
Interventional
Phase 1
Seattle, Washington, 98195, United States
We will administer two experimental drugs, acyline and oral testosterone. Acyline shots will be given on Day 0 to turn off the body's testosterone production for about 10-14 days.
The next day, Day 1, subjects begin taking 300 mg modified slow-release testosterone pill by mouth, three times a day, around 9 AM, 1 PM, and 7 PM for a total of 27 pills.
There are overnight stays on Day 1 and Day 9 to allow monitoring of blood testosterone levels over a 24 hour period, from @9 AM to 9 AM the next morning. At those visits, blood is drawn at baseline (before taking the pill) and at 1, 2, 4, 5, 6, 8, 10, 11, 12, 14, 16, and 24 hours after the morning dose.
Acyline is an experimental drug. The FDA allows its use only in research with a small number of volunteers. We have used acyline in over 125 men without serious side effects. The use of testosterone in this study is experimental and there may be unknown or unanticipated risks.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
300 ug/kg injection on Day 0
Time frame: baseline & day 9
initial pharmacokinetics [PK] (day 1) of oral testosterone dosed 3 times daily and the PK after 9 days of treatment
Time frame: baseline & day 9
initial 24-hour pharmacokinetics (PK) of oral testosterone dosed 3 times daily and post 24-hour PK after 9 days of treatment
Time frame: baseline & day 9
Time frame: baseline & day 9
Time frame: baseline & day 9
Time frame: baseline & day 9
Time frame: baseline & day 9
Time frame: baseline & day 9
Time frame: baseline & day 9
Free T normal range 4.7-18 ng/dL
Time frame: baseline & day 9
Free T normal range 4.7-18 ng/dL
University of Washington
Other
Pharmacokinetics of Modified Slow-Release Oral Testosterone Over 10 Days in Normal Men With Experimental Hypogonadism
Acronym: Oral T8
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07374406
Healthy
Jeonju, South Korea
View Trial DetailsNCT07365865
Deficient Keratinized Mucosa, Healthy
Cairo, Egypt
View Trial DetailsNCT04849923
Healthy
Winterthur, Canton of Zurich, Switzerland
View Trial DetailsNCT06744517
Behavior, Healthy
Toronto, Ontario, Canada
View Trial Details